Alterity Therapeutics Limited (NASDAQ:ATHE) traded with an addition of $0.02 to close at $0.32 on Thursday, an upside of 8.37 percent. An average of 193,032 shares of common stock have been traded in the last five days. There was a gain of $0.0183 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 84,093 shares traded, while the 50-day average volume stands at 71,643.
ATHE stock has decreased by -19.18% in the last month. The company shares reached their 1-month lowest point of $0.2900 on 12/28/22. With the stock rallying to its 52-week high on 01/06/22, shares of the company touched a low of $0.29 and a high of $1.23 in 52 weeks. It has reached a new high 3 times so far this year and lost -59.01% or -$0.3901 in price. In spite of this, the price is down -74.00% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Alterity Therapeutics Limited (ATHE) stock’s beta is 1.17. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.77, the price-to-book (PB) ratio at 0.50.
The quick ratio of Alterity Therapeutics Limited for the recent quarter was 7.10, and the current ratio was 7.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter. Its gross profit as reported stood at $12.72 million.
From a technical analysis perspective, let’s take a brief look at Alterity Therapeutics Limited (ATHE) price momentum. RSI 9-day as of the close on 28 December was 54.19%, suggesting the stock is Neutral, with historical volatility in this time frame at 65.43%.
As of today, ATHE’s price is $0.3093 +5.87% or $0.0183 from its 5-day moving average. ATHE is currently trading -8.97% lower than its 20-day SMA and -48.45% lower than its 100-day SMA. However, the stock’s current price level is -25.11% below the SMA50 and -53.70% below the SMA200.
The stochastic %K and %D were 23.27% and 14.33%, respectively, and the average true range (ATR) was 0.0249. With the 14-day stochastic at 44.33% and the average true range at 0.0248, the RSI (14) stands at 47.29%. The stock has reached 0.0005 on the 9-day MACD Oscillator while the 14-day reading was at -0.0064.
The consensus rating for Alterity Therapeutics Limited (ATHE) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ATHE, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ATHE’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $2.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Alterity Therapeutics Limited (ATHE) stock is $2.00.